A recent study conducted by Dandelion Health suggests that GLP-1 drugs such as Ozempic, Mounjaro, Wegovy, and Zepbound could potentially prevent more than 34,000 heart attacks and strokes annually in the United States. These medications, typically used to treat diabetes and aid in weight loss, have shown promising cardiovascular benefits in previous clinical trials.
The study by Dandelion Health focused on individuals with mild or moderate cardiovascular disease who had not previously experienced a heart attack or stroke. By analyzing real-world data using AI-driven algorithms, the researchers found that patients taking GLP-1 drugs had a lower cardiovascular risk after three years compared to those not taking the medications.
While the results of the study are promising, it is important to note that the research has not yet been peer-reviewed. Despite this, the findings suggest that GLP-1 drugs could serve as a primary prevention method for heart attacks and strokes in patients with obesity and mild or moderate CVD.
Experts in the field, such as Cardiologist Chad S. Weldy, MD, PhD, acknowledge the potential benefits of GLP-1 drugs for cardiovascular disease prevention. However, they caution that more research, including large-scale clinical trials, will be necessary before these medications can be widely prescribed for primary prevention of CVD.
The cost and feasibility of conducting such large trials, as well as the potential challenges of prescribing expensive lifelong medications to tens of millions of Americans, are important considerations in the discussion of expanding the use of GLP-1 drugs for CVD prevention.
In conclusion, while the research conducted by Dandelion Health shows promising results, further studies will be needed to fully assess the effectiveness and implications of using GLP-1 drugs for primary prevention of cardiovascular disease.